Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.

ABSTRACT:

Background

Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy.

Methods

We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up.

Results

65 patients were included. Among them, 32 were treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients)

SUBMITTER: Campochiaro C 

PROVIDER: S-EPMC7242960 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature